Surrozen Inc (SRZN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Surrozen Inc stock (SRZN) is currently trading at $25.00. Surrozen Inc PS ratio (Price-to-Sales) is 59.81. Analyst consensus price target for SRZN is $37.50. WallStSmart rates SRZN as Sell.
- SRZN PE ratio analysis and historical PE chart
- SRZN PS ratio (Price-to-Sales) history and trend
- SRZN intrinsic value — DCF, Graham Number, EPV models
- SRZN stock price prediction 2025 2026 2027 2028 2029 2030
- SRZN fair value vs current price
- SRZN insider transactions and insider buying
- Is SRZN undervalued or overvalued?
- Surrozen Inc financial analysis — revenue, earnings, cash flow
- SRZN Piotroski F-Score and Altman Z-Score
- SRZN analyst price target and Smart Rating
Surrozen Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Surrozen Inc (SRZN) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Surrozen Inc (SRZN) Key Strengths (1)
124.57% of shares held by major funds and institutions
Supporting Valuation Data
Surrozen Inc (SRZN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -90.20%, a shrinking business
Very expensive at 59.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
Surrozen Inc (SRZN) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (59.81), Price/Book (2.22) suggest expensive pricing. Growth concerns include Revenue Growth at -90.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -62.80%, Operating Margin at -1107.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -62.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -90.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SRZN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SRZN's Price-to-Sales ratio of 59.81x trades 311% above its historical average of 14.55x (86th percentile), historically expensive. The current valuation is 12% below its historical high of 68.02x set in Mar 2026, and 22052% above its historical low of 0.27x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~8.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Surrozen Inc (SRZN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Surrozen Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 4M with 90% decline year-over-year.
Key Findings
Debt-to-equity ratio of -0.30 indicates a conservative balance sheet with 81M in cash.
Spending 249% of revenue (9M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 90% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Surrozen Inc.
Bottom Line
Surrozen Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Surrozen Inc(SRZN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.